SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
InterMune (nasdaq)ITMN
An SI Board Since March 2000
Posts SubjectMarks Bans Symbol
508 36 0 ITMN
Emcee:  Secret_Agent_Man Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
383BofA upgrading ITMN to Buy from Neutral This is surprise to me. Perhaps, they IRWIN JAMES FRANKEL-7/2/2003
382InterMune Announces Executive Management Change Monday June 30, 8:32 am ET - BoIRWIN JAMES FRANKEL-6/30/2003
381Goodkind Labaton Rudoff & Sucharow LLP Files Class Action Lawsuit Against InIRWIN JAMES FRANKEL-6/26/2003
380Intermune stock falls on warning Brisbane biotech firm scales back sales projectsim1-6/14/2003
379RECAP OF TODAYS CC This morning ITMN hosted a CC and webcast covering the PRIRWIN JAMES FRANKEL-6/12/2003
378Press Release Source: InterMune, Inc. InterMune Announces Positive Top-Line Phtnsaf-6/11/2003
377Ftom TSC... <i>Intermune Blows Up After Hours By Troy Wolverton Staff Rtnsaf-6/11/2003
376InterMune Announces Interim Data Showing High Early Virologic Response To InfergIRWIN JAMES FRANKEL-5/19/2003
375<i>Pre-clinical studies of GC-1008, a human anti-panTGFbeta monoclonal antnigel bates-5/19/2003
374InterMune Announces Favorable New Clinical Results of Actimmune(R) In IdiopathicIRWIN JAMES FRANKEL-5/19/2003
373Intermune Announces Results of Actimmune Biomarker Study In Idiopathic PulmonaryIRWIN JAMES FRANKEL-5/19/2003
372Randomized, Double-Blind, Placebo-Controlled Study of Interferon Gamma-1b (IFN- IRWIN JAMES FRANKEL-5/14/2003
371InterMune Announces Promising Clinical Results With Actimmune for IPF To Be PresIRWIN JAMES FRANKEL-5/14/2003
370InterMune Announces Potent Antibiotic Activity of Oritavancin In In Vitro StudieIRWIN JAMES FRANKEL-5/12/2003
369Press Release Source: InterMune, Inc. InterMune Announces Results From Phase IIRWIN JAMES FRANKEL-5/9/2003
368Revenues on the low end of the range, but earnings much better than expected. Dtuck-4/29/2003
367Talking Up a Drug for This (and That)[NYT] By ANDREW POLLACK April 27, 2003 TDoc Bones-4/27/2003
366Mr. Market unimpressed by this, nevertheless, we can mark our calendars: >&gtuck-4/9/2003
365One question I'd have about the article is how they can credit actimmune as rkrw-4/2/2003
364thestreet.com About recent safety concerns for Actimmune when given to advancedtuck-4/1/2003
363InterMune Provides Update on Applied Research Programs in Hepatitis C At CytokinIRWIN JAMES FRANKEL-3/31/2003
362Small increase in SI: Mar. 14, 2003 5,808,196 504,277 11.52 Feb. 14, 2003 5,73IRWIN JAMES FRANKEL-3/26/2003
361Well Peter, I have rejoined the good side of the force - long ITMN. Also - FWIIRWIN JAMES FRANKEL-3/19/2003
360sfgate.com The dilemma of a dying man Patient sues to get unproven drug that mrkrw-2/21/2003
359IJ, I re-entered with a small position. FWIW. PeterBiomaven-2/20/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News